Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Volatility & Risk
Spectral Diagnostics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.
Institutional and Insider Ownership
1.2% of ENDRA Life Sciences shares are owned by institutional investors. 1.5% of Spectral Diagnostics shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spectral Diagnostics | $1.75 million | 169.35 | -$34.13 million | ($0.10) | -10.10 |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.15) | -0.66 |
ENDRA Life Sciences has lower revenue, but higher earnings than Spectral Diagnostics. Spectral Diagnostics is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Spectral Diagnostics and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spectral Diagnostics | -1,378.12% | N/A | -581.29% |
| ENDRA Life Sciences | N/A | -433.64% | -204.58% |
Analyst Recommendations
This is a breakdown of current ratings for Spectral Diagnostics and ENDRA Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spectral Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
ENDRA Life Sciences has a consensus target price of $30.00, indicating a potential upside of 459.70%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Spectral Diagnostics.
Summary
ENDRA Life Sciences beats Spectral Diagnostics on 9 of the 13 factors compared between the two stocks.
About Spectral Diagnostics
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
